Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Actinium Pharmaceuticals Inc (NY: ATNM )

1.800 -0.080 (-4.26%)
Streaming Delayed Price Updated: 3:59 PM EDT, Oct 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 337,832
Open 1.880
Bid (Size) 1.800 (39)
Ask (Size) 1.810 (19)
Prev. Close 1.880
Today's Range 1.800 - 1.920
52wk Range 1.330 - 10.24
Shares Outstanding 21,331,314
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Actinium Pharmaceuticals, Inc. (ATNM) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Actinium Pharmaceuticals, Inc. (ATNM) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire

Performance

YTD
-66.17%
-66.17%
1 Month
-2.17%
-2.17%
3 Month
-77.50%
-77.50%
6 Month
-74.14%
-74.14%
1 Year
-66.67%
-66.67%

More News

Read More
ATNM Investors Have Opportunity to Join Actinium Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
ATNM Stock Earnings: Actinium Pharmaceuticals Beats EPS for Q2 2024
Via InvestorPlace
Why Palantir Technologies Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket
Via Benzinga
S&P 500 Down Over 100 Points; Actinium Pharmaceuticals Shares Plunge
Via Benzinga
Topics Stocks
Exposures US Equities
Dow Tumbles 950 Points; ISM Services PMI Surges In July
Via Benzinga
Topics Stocks
Exposures US Equities
Actinium Pharmaceuticals Receives FDA Request For Additional Studies On Leukemia Treatment
Via Benzinga
Exposures Product Safety
Nasdaq Tumbles 3%; Tyson Foods Earnings Top Views
Via Benzinga
3 Under-$10 Biotech Stocks That Could Make You Rich
Via InvestorPlace
3 Clinical-Stage Biotech Stocks to Buy for Multibagger Returns
Via InvestorPlace
Treatment of Blood Cancers - Biopharma Companies Building out their Pipeline of Solutions
Via Newsfile
Actinium Presents Exciting Data On Leukemic Cell Killing in Preclinical Acute Myeloid Leukemia Models at the 2024 EHA Congress
Via AB Newswire
Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase
Via FinancialNewsMedia
Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies
Via FinancialNewsMedia
Acute Myeloid Leukemia Market Size Expected to Reach $2.97 Billion By 2029 as Clinical Trials Increase
From FN Media Group LLC
Via GlobeNewswire
Biopharma Stocks Quest for Solutions for Acute Myeloid Leukemia (AML)
Via Newsfile
Actinium Presents First Ever Data Demonstrating Statistically Significant Anti-Tumor Control and Potent Leukemic Cell Killing with Actimab-A in Combination with Leading Menin Inhibitors in Preclinical Acute Myeloid Leukemia Models at the 2024 EHA Congress
Via FinancialNewsMedia
Actinium Pharmaceuticals (ATNM) Reveals Promising Results from SIERRA Trial at EHA Congress
Via AB Newswire
Topics Intellectual Property
Exposures Intellectual Property
Under-$10 Picks: 3 Biotech Stocks That Can Double Before the End of 2024
Via InvestorPlace
Meme Mania Meets Medicine: 3 Biotech Stocks Primed to Soar
Via InvestorPlace
3 Cheap Biotech Stocks to Buy Now: May 2024
Via InvestorPlace
Exposures Product Safety
Actinium Pharmaceuticals (ATNM) Poised for Breakout as Analysts Project Significant Upside
Via AB Newswire
Actinium Pharmaceuticals (NYSE: ATNM): A Prime Target in a Wave of Radiopharmaceutical Mergers and Acquisitions
Via AB Newswire
ATNM Stock Earnings: Actinium Pharmaceuticals Beats EPS for Q1 2024
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.